Related Experiment Videos
Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia
M A Kari1, K Heinonen, R S Ikonen
1Children's Hospital, University of Helsinki, Finland.
Insights
Early dexamethasone treatment improved short-term lung function in premature infants, particularly girls, without serious side effects. Long-term benefits for bronchopulmonary dysplasia were not clearly established.
Area of Science:
- Neonatology
- Pediatric Pulmonology
- Endocrinology
Background:
- Bronchopulmonary dysplasia (BPD) is a significant complication in preterm infants.
- Corticosteroids are used to manage BPD, but their optimal timing and effects on adrenal function require further investigation.
Purpose of the Study:
- To evaluate the efficacy of a one-week course of dexamethasone in reducing BPD severity in preterm infants.
- To assess the impact of this treatment on infant adrenal function.
Main Methods:
- A randomized, double-blind, placebo-controlled study.
- Forty-one ventilator-dependent preterm infants (mean birth weight 880g, gestational age 27 weeks) were enrolled.
- Treatment involved a one-week course of dexamethasone or placebo.
Main Results:
- Pulmonary outcome at 28 days was significantly better in female infants treated with dexamethasone.
- No significant long-term outcome differences were observed, except for reduced supplemental oxygen need in treated females.
- A transient suppression of basal cortisol and adrenal response to ACTH was noted post-treatment.
Conclusions:
- Early, short-term dexamethasone treatment can improve short-term pulmonary outcomes in preterm infants.
- Evidence for long-term benefits of this specific treatment regimen for BPD is limited.
- The treatment showed a temporary impact on adrenal function without serious adverse events.
Abstract:
A randomised double blind placebo controlled study was conducted to determine whether a one week course of dexamethasone could reduce the severity of bronchopulmonary dysplasia in preterm infants without compromising their adrenal function. Forty one infants with a mean birth weight of 880 g and a gestational age of 27 weeks who were ventilator dependent at 10 days of age were enrolled. At the age of 28 days pulmonary outcome was significantly better in the girls treated with dexamethasone but not in all infants. There was no difference between the groups in the long term outcome, except for a shorter duration of supplemental oxygen in dexamethasone treated female infants. After the one week dexamethasone treatment there was a significant but short lived suppression of the basal cortisol concentrations and the adrenal response to corticotrophin (ACTH). No serious side effects were observed. It is concluded that early one week dexamethasone treatment improves short term pulmonary outcome in premature infants, but there is no clear evidence of long term benefits.